-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓USDISIN US04280A1007
ISIN US04280A1007
WKN A2AGYB
Symbol ARWR
Währung
USD
Firmenname
Arrowhead Pharmaceuticals, Inc
Marktkapitalisierung
8.114.998.048 (+- 5%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
8.484.996.096 oder 7.745.000.000
Mitarbeiter
315 (+- 26%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
232 oder 397 Mitarbeiter
KGV
478.56
EBITDA 5.857.247
PEGRatio -1.32
Buchwert 4.404
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 75,84 EUR +1,88%
Portrait der Arrowhead Pharmaceuticals Aktie
Das Unternehmen Arrowhead Pharmaceuticals, Inc aus USA beschäftigt 315 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharma tätig.
Das Unternehmen Arrowhead Pharmaceuticals, Inc ist nur in 7 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter iShares Nasdaq US Biotechnology UCITS ETF gewichtet Arrowhead Pharmaceuticals mit 0,50% im ETF.
Entdecke die 6 ETFs in denen Arrowhead Pharmaceuticals, Inc am höchsten gewichtet ist Insgesamt in 7 ETFs enthalten
Dir gefallen die Informationen zu Arrowhead Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Arrowhead Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Arrowhead Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Arrowhead Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
38 News & Informationen zur Arrowhead Pharmaceuticals Aktie
Is Arrowhead Pharmaceuticals (ARWR) A Good Stock To Buy Now?
Baron Opportunity Fund recently published its second-quarter commentary – a copy of which can be downloaded here.
Acuta Capital Partners, Llc Buys BCLS Acquisition Corp, Vincerx Pharma Inc, Cyteir Therapeutics Inc, Sells 89bio Inc, Curis Inc, Trillium Therapeutics Inc
GuruFocus Article or News written by insider and the topic is about:
Friday Afternoon Analyst Upgrades and Downgrades: Carnival, Duke Energy, Petco Health and More – 24
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including American Water Works, Carnival, Duke Energy, Okta and Zscaler.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results – Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2021 Earnings Conference Call August 5, 2021 16:30 ET Company Participants Vincent Anzalone – Vice President, Investor Relations Christopher…
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of …
Arrowhead Pharmaceuticals FQ3 2021 Earnings Preview (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to announce Q3 earnings results on Thursday, August 5th, after market close.The consensus EPS Estimate is -$0.14 (-7.7% Y/Y) and…
Oak Ridge Investments Llc Buys Wingstop Inc, Vicor Corp, Q2 Holdings Inc, Sells NeoGenomics Inc, Arrowhead Pharmaceuticals Inc, Proofpoint Inc
GuruFocus Article or News written by insider and the topic is about:
Should I Avoid ADT Inc. (ADT)?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually…
Global Nanobiotechnology Applications And Markets 2021-2026: Molecular Diagnostic, Therapeutics, & Biopharmaceutical Application
DUBLIN, July 27, 2021 /PRNewswire/ — The
Is TFII Stock A Buy or Sell?
We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the…
Here is What Hedge Funds Think About Arrowhead Pharmaceuticals Inc. (ARWR)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Western Financial Corporation Buys iShares 1-3 Year Credit Bond ETF, Tesla Inc, Square Inc, Sells Netflix Inc, Qualcomm Inc, Salesforce.com Inc
GuruFocus Article or News written by insider and the topic is about:
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. ARWR today announced that as an inducement to entering into employment with the Company, on July 1, 2021, the Compensation
Arrowhead Pharmaceuticals To Webcast Fiscal 2021 Third Quarter Results
Arrowhead Pharmaceuticals Inc. ARWR today announced that it will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial
Russell 2000 Traders Place Bearish Bets Via IWM ETF
The iShares Russell 2000 ETF (NYSE:IWM) has been trading sideways for the better part of the last six months between $211 and its all-time hi…
Coty Inc (COTY): Hedge Funds Are Snapping Up
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However…
Where Do Hedge Funds Stand On Denali Therapeutics Inc. (DNLI)?
In this article we will check out the progression of hedge fund sentiment towards Denali Therapeutics Inc. (NASDAQ:DNLI) and determine whether it is a…
6 Top Nanotechnology Uses
What are the top nanotechnology uses in the world today? We run through six ways nanotechnology makes a difference in daily life.
Will Arrowhead Stock Rebound After A Large 30% Decline Last Week?
The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided to pause its early stage clinical trials for AROENaC1001, the company’s investigational treatment.
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leadin…
10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
In this article, we will discuss the 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. If you want to skip our detailed analysis…
Hedge Funds Are Dumping Lumentum Holdings Inc (LITE)
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter,…
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.44% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.44%
Alector, Virgin Galactic rise; Arrowhead, Boeing fall
Stocks that traded heavily or had substantial price changes Friday: Alector, Virgin Galactic rise; Arrowhead, Boeing fall
Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to …
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
A paused clinical trial with an important asset wasn't what investors wanted to hear today.
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
Arrowhead Pharmaceuticals Inc. ARWR today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is
Arrowhead Pharmaceuticals Initiates Phase 2b Study Of Investigational ARO-ANG3 For Treatment Of Mixed Dyslipidemia
Arrowhead Pharmaceuticals Inc. ARWR today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company's
Arrowhead Pharmaceuticals : Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
Arrowhead Pharmaceuticals Inc. today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the… | June 26, 2021
Stocks That Hit 52-Week Highs On Wednesday
This morning 122 companies reached new 52-week highs.
Interesting Facts: The largest company on a market cap basis to set a new 52-week high …
Arrowhead Presents Positive Interim Clinical Data On ARO-HSD Treatment In Patients With Suspected NASH At EASL International Liver Congress
Arrowhead Pharmaceuticals Inc. ARWR today presented positive interim results from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company's
Arrowhead Pharmaceuticals : Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) (Form 8-K)
– Horizon to receive a worldwide exclusive license for an investigational short interfering RNA therapeutic targeting xanthine dehydrogenase
PASADENA,… | June 22, 2021
Arrowhead Pharmaceuticals And Horizon Therapeutics Announce Collaboration To Develop RNAi Therapeutic For Uncontrolled Gout
Arrowhead Pharmaceuticals Inc. ARWR and Horizon Therapeutics plc HZNP today announced a global collaboration and license agreement for ARO-XDH, a previously
Arrowhead Pharmaceuticals : to Webcast Fiscal 2021 Second Quarter Results
Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended… | April 16, 2021
Arrowhead Pharmaceuticals To Webcast Fiscal 2021 Second Quarter Results
Arrowhead Pharmaceuticals Inc. ARWR today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial
Arrowhead Pharmaceuticals : Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Arrowhead Pharmaceuticals, Inc. today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule … | April 15, 2021
Arrowhead Pharmaceuticals: Good Entry Point For Long-Term Investors (NASDAQ:ARWR)
Arrowhead is a leader in RNAi-based biotech drug development. See why the stock price is an excellent entry point for long-term investors.
Opinion: Biotech stocks are a buy — especially these 18 picks
The sector's recent pullback offers an chance to get into exciting areas of biotech research like gene editing and oncology at better prices.